Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT2A | Q92830 | 1/20 | 0.39 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 7/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 7/20 | 0.38 |
| ▸ | MGLL | Q99685 | 5/20 | 0.38 |
| ▸ | FAAH | O00519 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | BLM | P54132 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.36 |
| ▸ | GMNN | O75496 | 1/20 | 0.36 |
| ▸ | THPO | P40225 | 1/20 | 0.36 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | WRN | Q14191 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18553064 | 0.85 | HSD17B10 (0.39) | PTGS1PTGS2MGLLFAAHALDH1A1 | |
| SCHEMBL15892774 | 0.84 | HPGD (0.37) | KAT2AKAT2BPTGS1PTGS2MGLL | |
| SCHEMBL20470971 | 0.83 | KAT2A (0.39) | KAT2AKAT2BPTGS1PTGS2MGLL | |
| SCHEMBL26554900 | 0.82 | KAT2A (0.35) | KAT2AKAT2BPTGS1PTGS2MGLL | |
| SCHEMBL2226946 | 0.81 | PTGS1 (0.42) | KAT2AKAT2BPTGS1PTGS2MGLL | |
| SCHEMBL2754833 | 0.80 | PTGS1 (0.44) | PTGS1PTGS2MGLLFAAHALDH1A1 | |
| SCHEMBL12107529 | 0.79 | ALDH1A1 (0.39) | PTGS1PTGS2MGLLFAAHALDH1A1 | |
| SCHEMBL15489016 | 0.79 | MGLL (0.34) | MGLLHPGDCYP2C19OPRM1OPRD1 | |
| SCHEMBL23395065 | 0.78 | PTGS1 (0.38) | PTGS1PTGS2MGLLFAAHALDH1A1 | |
| SCHEMBL14655039 | 0.78 | PTGS1 (0.40) | KAT2AKAT2BPTGS1PTGS2MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8034981-B2 | Modified bio-related substance, process for producing the same, and intermediate | NOF CORPORATION (JP) | 2011-10-11 | — | — | US | disclosed |
| US-20110082277-A1 | MODIFIED BIO-RELATED SUBSTANCE, PROCESS FOR PRODUCING THE SAME, AND INTERMEDIATE | NOF CORPORATION (JP) | 2011-04-07 | — | — | US | disclosed |
| US-7851491-B2 | Modified bio-related substance, process for producing the same, and intermediate | NOF CORPORATION (JP) | 2010-12-14 | — | — | US | disclosed |
| US-20090280106-A1 | Pituitary adenylate cyclase acivating peptide (pacap) receptor (vpac2) agonists and their pharmacological methods of use | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-11-12 | — | — | US | disclosed |
| US-20090192320-A1 | MODIFIED BIO-RELATED SUBSTANCE, PROCESS FOR PRODUCING THE SAME, AND INTERMEDIATE | NOF CORPORATION (JP) | 2009-07-30 | — | — | US | disclosed |
| US-20090171071-A1 | PYY Agonists and Uses Thereof | PFIZER INC. | 2009-07-02 | — | — | US | disclosed |
| US-20090170778-A1 | PYY Agonists and Uses Thereof | PFIZER INC. | 2009-07-02 | — | — | US | disclosed |
| US-7524875-B2 | Modified bio-related substance, process for producing the same, and intermediate | NOF CORPORATION (JP) | 2009-04-28 | — | — | US | disclosed |
| US-20090005297-A1 | Aprotinin Variants | BAYER HEALTHCARE AG (DE) | 2009-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192320-A1 | MODIFIED BIO-RELATED SUBSTANCE, PROCESS FOR PRODUCING THE SAME, AND INTERMEDIATE | BMP1, BMP2, AQP1 | KAT2A 2322/4885KAT2B 2886/4885PTGS1 41/4885 |
| US-20090280106-A1 | Pituitary adenylate cyclase acivating peptide (pacap) receptor (vpac2) agonists and their pharmacological methods of use | ADCYAP1R1, VIPR2, ADCY2 | KAT2A 1405/4885KAT2B 2453/4885PTGS1 2785/4885 |
| US-20090171071-A1 | PYY Agonists and Uses Thereof | NPY1R, NPY2R, NPY4R | KAT2A 4198/4885KAT2B 4561/4885PTGS1 1536/4885 |
| US-20090170778-A1 | PYY Agonists and Uses Thereof | NPY1R, NPY2R, NPY4R | KAT2A 4198/4885KAT2B 4561/4885PTGS1 1536/4885 |
| US-20090005297-A1 | Aprotinin Variants | PRSS1, SPINT2, SERPINB1 | KAT2A 4401/4885KAT2B 4329/4885PTGS1 988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.